Skip to main navigation
Skip to search
Skip to main content
Sort by
Keyphrases
Mild Cognitive Impairment
100%
Memory Clinic
60%
Roflumilast
48%
Subjective Cognitive Decline
48%
Speech Features
40%
Cognitive Performance
37%
Verbal Learning Test
35%
Clinic Population
35%
Early Diagnostics
32%
Semi-automated
32%
Speech Biomarkers
32%
Nootropic
32%
Cognitive Impairment
27%
Linguistic Features
26%
Machine Learning Classifiers
26%
Semantic Verbal Fluency
26%
All Cognitive Disorders/dementia
26%
Verbal Learning Task
24%
Phosphodiesterase 4 Inhibitor
24%
Neurocognitive Disorders
22%
Healthy Elderly
22%
Clinical Validation
21%
Word Frequency
21%
Speech Analysis
20%
Elderly Participants
19%
Clinically Significant
18%
Smartphone
18%
Automatic Speech Recognition
17%
Cognitive Function
17%
Verbal Memory
16%
Memory Feature
16%
Risk Insights
16%
Satisfaction Survey
16%
Individuals at Risk
16%
Subject Trials
16%
Automated Speech Analysis
16%
Dementia Prevention
16%
Reliability Validation
16%
Enhancing Memory
16%
Luxembourg
16%
Runcaciguat
16%
Cognitive Task
16%
Luteolin
16%
Alzheimer's Disease Dementia
16%
Cost-effectiveness
16%
Cognition Enhancement
16%
Organoid Models
16%
Neuropsychiatric Symptoms
16%
Synapse
16%
Randomized Placebo-controlled Trial
16%
Neuroscience
Mild Cognitive Impairment
78%
Biological Marker
36%
Nootropic
32%
Subjective Cognitive Decline
30%
Placebo
24%
Alzheimer's Disease
22%
Phosphodiesterase-4 Inhibitor
21%
Cognitive Disorders
18%
Linguistics
18%
Cognitive Function
17%
Synapse
16%
Organoid
16%
Verification and Validation
16%
Luteolin
16%
Roflumilast
16%
Neuropsychiatric Symptom
16%
In Vivo
16%
Guanylate Cyclase
16%
Phosphodiesterase
14%
Event-Related Potential
14%
Cognitive Decline
11%
Cognitive Tests
8%
Synapse Formation
8%
Second Messenger System
6%
Speech Recognition
6%
Phosphodiesterase Inhibitor
6%
Episodic Memory
6%
Heme
5%
Clinical Dementia Rating
5%
Forskolin
5%
Beta-Glucuronidase
5%
Blood Plasma
5%
Cyclic Adenosine Monophosphate
5%
Intracellular Signaling
5%
Adenylyl Cyclase
5%
Enzymes
5%
